Cincinnati, OH. July 26, 2012 – Congenital hypothyroidism is thyroid hormone deficiency at birth that, if left untreated, can lead to neurocognitive impairments in infants and children. Although the World Health Organization recommends 200-300 µg of iodine daily during pregnancy for normal fetal thyroid hormone production and neurocognitive development, the US Institute of Medicine considers 1,100 µg to be the safe upper limit for daily ingestion. A case series scheduled for publication in The Journal of Pediatrics describes three infants who developed congenital hypothyroidism as a result of excess maternal iodine supplementation.
Kara Connelly, MD, and colleagues from Oregon Health & Science University, Doernbecher Children's Hospital, Boston University School of Medicine, State of Oregon Public Health Laboratory, and Randall Children's Hospital at Legacy Emanuel describe three infants with congenital hypothyroidism whose mothers had taken 12.5 mg of iodine daily, 11 times more than the safe upper limit, while pregnant and/or breastfeeding. Iodine is transferred from the mother to the infant through the placenta or breast milk. The three infants had blood iodine levels 10 times higher than healthy control infants (measured from newborn screening filter paper).
Excess iodine causes the thyroid to temporarily decrease function to protect against hyperthyroidism (Wolff-Chaikoff effect). Adults and older children are able to "escape" from this effect after several days of excess iodine to avoid hypothyroidism. However, the immature thyroid glands of fetuses and newborns have not developed this protective effect and are more susceptible to iodine-induced hypothyroidism. Although infants recover normal thyroid function after acute iodine exposure (e.g., a few days of topical iodine application), continuous excessive iodine exposure to the fetal and neonatal thyroid gland may cause long-term harmful effects on thyroid function.
Sources of iodine include nutritional supplements, prenatal vitamins, and seaweed (kelp). According to Dr. Connelly, "The use of iodine-containing supplements in pregnancy and while breastfeeding is recommended in the United States. However, these cases demonstrate the potential hazard of exceeding the safe upper limit for daily ingestion." Excess iodine ingestion from supplementation is often unrecognized because it is not routine practice to ask mothers of infants with congenital hypothyroidism about nutritional supplements taken during pregnancy. Pregnant or breastfeeding women should discuss the safe dosages of nutritional supplements with their doctors prior to including them in their daily regimen.
Notes for editors
"Congenital Hypothyroidism Caused by Excess Prenatal Maternal Iodine Ingestion" by Kara Connelly, MD, Bruce Boston, MD, Elizabeth Pearce, MD, David Sesser, David Snyder, MD, Lewis Braverman, MD, Sam Pino, Stephen LaFranchi, MD, appears in The Journal of Pediatrics (www.jpeds.com), DOI 10.1016/j.jpeds.2012.05.057, published by Elsevier.
For an interview with Kara Connelly, MD, contact Tamara Hargens-Bradley, +1 503 494 8231, firstname.lastname@example.org.
About the Journal of Pediatrics
The Journal of Pediatrics is a primary reference for the science and practice of pediatrics and its subspecialties. This authoritative resource of original, peer-reviewed articles oriented toward clinical practice helps physicians stay abreast of the latest and ever-changing developments in pediatric medicine. The Journal of Pediatrics is ranked 4th out of 113 pediatric medical journals (2011 Journal Citation Reports, Thomson Reuters 2012). URL: www.jpeds.com
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 513 636 7140